UNIVERSITY OF SOUTHERN CALIFORNIA

NeOnc Technologies has appointed two distinguished Duke University neuro-oncologists, Dr. David M. Ashley and Dr. Henry S. Friedman, to its scientific advisory board to guide development of CNS cancer therapies.

UHealth-University of Miami Health System has enrolled the first two patients in Aclarion's pivotal CLARITY trial, testing Nociscan technology for chronic low back pain surgical outcomes.

Adagene's ADG126, a masked anti-CTLA-4 therapy, achieved a ~30% objective response rate with durable responses in microsatellite stable colorectal cancer patients who had failed previous treatments.

Researchers at the University of Gothenburg found that semaglutide, a diabetes and weight loss medication, reduced cocaine self-administration by 26% in rats compared to control animals.

NeOnc Technologies received FDA authorization to proceed with Phase IIa/IIb clinical trial of NEO212, a first-in-class oral chemical conjugated chemotherapy candidate for brain cancer.

Cancer treatments including chemotherapy, radiation therapy, and surgery can severely impact fertility in reproductive-age patients, making early fertility preservation counseling essential.

An FDA expert panel convened to reassess boxed warnings for menopausal hormone therapy, with multiple experts arguing that current labels overstate risks and are not supported by comprehensive scientific evidence.

NeOnc Technologies signed a non-binding term sheet with Quazar Investment for a $50 million equity investment to establish a UAE-based clinical platform focused on the Middle East and North Africa region.

Mendaera received FDA 510(k) clearance for its Focalist handheld robotic system designed to enhance precision in ultrasound-guided needle placement procedures.

A recent study published in JAMA Network Open reveals that maternal obesity, gestational diabetes, and hypertensive disorders during pregnancy are associated with elevated blood pressure in offspring.